Identification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease.
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentral Hospital, Nancy, France
About this trial
The MICROSPA project aims to compare gut microbiota, serum cytokines, and PBMC of patients suffering from Crohn's disease (CD) associated or not to spondylarthritis (SpA). 3 groups of patients will be analyzed: patients suffering from CD alone, patients suffering from SpA alone, patients suffering from CD and SpA. One group of healthy controls will be analysed as a comparator. Fecal microbiota will be determined by bacteriome, virome and fungome NGS sequencing
Eligibility criteria
Qualifiers
Age ≥ 18 years.
Patients with Crohn's disease and axial spondyloarthritis according to the criteria below.
Patients with Crohn's disease (MC patients) with a diagnosis established according to clinical, biological criteria, radiological, endoscopic and / or histological studies for 3 months. With diagnosis of exclusion of a spondyloarthritis on criteria ASAS and / or New York modified.
Patients with axial spondyloarthritis (SpA patients) with a diagnosis based on modified ASAS and / or New York criteria with exclusion diagnosis of Crohn's disease.
Disqualifiers
History of colonic resection
Taking antibiotics or colon preparation for colonoscopy within 8 weeks before stool collection (Temporary contraindication = removal possible before colic or first bowel preparation after the start of colonic preparation).
Ostomy at the time of sampling
BMI> 30
Trial design
Treatments tested in this trial
- Microbiota Sequencing
Treatment groups
240 Participants
are divided into 4 treatment groupsSponsors and collaborators
Central Hospital, Nancy, France
Lead sponsor
Centre Hospitalier Régional Metz-Thionville
Collaborator
University Hospital, Strasbourg, France
Collaborator
Saint Antoine University Hospital
Collaborator
Source ClinicalTrials.gov